XML 16 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Total
Common Stock
Additional Paid In Capital
Retained Earnings
Unearned ESOP Shares
Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2024   17,527,709        
Balance at beginning of period at Dec. 31, 2024 $ 551,758,000 $ 175,000 $ 176,693,000 $ 380,541,000 $ (3,966,000) $ (1,685,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 14,539,000     14,539,000    
Cash dividends declared on common stock (2,054,000)     (2,054,000)    
Common stock repurchased (in shares)   (14,800)        
Common stock repurchased (503,000)   (503,000)      
Forfeited restricted stock (in shares)   (2,533)        
Retired stock (in shares)   (11,335)        
Retired stock $ (427,000)   (427,000)      
Granted restricted stock (in shares)   49,285        
Exercised stock options (in shares) 4,300 4,300        
Exercised stock options $ 96,000 $ 1,000 95,000      
Share-based compensation expense 490,000   490,000      
ESOP compensation expense 465,000   334,000   131,000  
Other comprehensive income (loss) 1,085,000         1,085,000
Balance at end of period (in shares) at Mar. 31, 2025   17,552,626        
Balance at end of period at Mar. 31, 2025 $ 565,449,000 $ 176,000 176,682,000 393,026,000 (3,835,000) (600,000)
Balance at beginning of period (in shares) at Dec. 31, 2025 17,286,289 17,286,289        
Balance at beginning of period at Dec. 31, 2025 $ 600,690,000 $ 173,000 166,856,000 436,524,000 (3,438,000) 575,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 16,772,000     16,772,000    
Cash dividends declared on common stock (2,169,000)     (2,169,000)    
Common stock repurchased (in shares)   (533,240)        
Common stock repurchased (23,081,000) $ (6,000) (23,075,000)      
Retired stock (in shares)   (21,975)        
Retired stock (579,000)   (579,000)      
Granted restricted stock (in shares)   54,111        
Granted restricted stock $ 1,000 $ 1,000        
Exercised stock options (in shares) 18,000 18,000        
Exercised stock options $ 59,000   59,000      
Share-based compensation expense 767,000   767,000      
ESOP compensation expense 569,000   437,000   132,000  
Other comprehensive income (loss) $ (622,000)         (622,000)
Balance at end of period (in shares) at Mar. 31, 2026 16,803,185 16,803,185        
Balance at end of period at Mar. 31, 2026 $ 592,407,000 $ 168,000 $ 144,465,000 $ 451,127,000 $ (3,306,000) $ (47,000)